Pluri Stock
Pluri Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Yaacov Yanay
- Employees
- 92
- Market cap
- $10 M
- IPO
- 30/06/2003
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on…
Pluri stock: price history
1D
-1.1%
1W
-2.4%
1M
-18.4%
6M
-74.3%
YTD
-68.9%
1Y
-78.6%
2Y
-81.2%
5Y
-95.6%
10Y
-99.2%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about Pluri
Analyst assessment of Pluri
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
No current analyst ratings available.
Pluri stock metrics
P/E
-0.38
P/B
-0.44
EV/EBITDA
-1.73
RETURN ON EQUITY
25.5%
NET MARGIN
-1,755.2%
DEBT/EQUITY
-1.52
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.2%
FLOAT SHARES
6,172,985
AVG. DAILY VOLUME (30D)
15,885
Insider transactions (SEC)
Manieu Alexandre Weinstein
SHORRER DORON
Manieu Alexandre Weinstein
Manieu Alexandre Weinstein
Manieu Alexandre Weinstein
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Pluri stock
What does Pluri do?
Pluri Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Yaacov Yanay, the company employs around 92 people.
The IPO was on 30/06/2003; the stock trades on NASDAQ under the ticker PLUR.
What do analysts say about Pluri stock?
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Pluri report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Pluri pay a dividend?
No, Pluri currently does not pay a dividend.
Which stocks are comparable to Pluri?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Pluri stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pluri against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.